Access cutting-edge heart transplant treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.
Access heart transplant specialists in New York at no cost
This study follows strict safety protocols and ethical guidelines
All study-related heart transplant treatment provided free
This is a phase 2, prospective, multi-center, open-label clinical trial. Sixty-six (66) primary heart transplant recipients will be randomized (1:2) to receive either standard-of-care, tacrolimus-based immunosuppression, or a belatacept-based regimen with gradual tacrolimus withdrawal over 9-months post-transplant. Both study arms will receive CellCept® (mycophenolate mofetil- MMF) or Myfortic® (mycophenolate sodium). Corticosteroids will be continued throughout the study in the belatacept arm.
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Check if you qualify for this heart transplant clinical trial in New York, NY
If you're searching for heart transplant treatment options in New York, NY, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced heart transplant specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.